@article{JTD19778,
author = {Masaru Katoh},
title = {Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {3},
year = {2018},
keywords = {},
abstract = {Therapeutics targeting epigenetic regulators (1-3), immune modulators (4-6) and receptor tyrosine kinases (7-9) have emerged as promising drugs for cancer patients who are refractory to conventional chemotherapy, radiotherapy or surgery (Figure 1). These cutting-edge therapeutics, together with next-generation sequencing (NGS) technologies that produce bulk genomics-related data as commodities of clinical medicine, have led to a gradual shift toward personalized or precision medicine.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/19778}
}